Ionis partner Novartis: pelacarsen Phase 3 Lp(a)HORIZON misses primary CV endpoint

IONIS PHARMACEUTICALS INC

Pelacarsen Phase 3 Lp(a)HORIZON did not meet primary endpoint of reducing CV events vs placebo (CV death, non-fatal MI/stroke, urgent revascularization).
Substantially lower Lp(a) levels achieved consistent with prior studies; acceptable safety profile; full data at upcoming medical congress.
Ionis discovered pelacarsen; Novartis licensed rights in Feb 2019; CEO Monia says results inform future cardiovascular care.
Ionis continues independent commercialization of TRYNGOLZA, DAWNZERA, ZANVASTRO; pipeline otherwise unaffected.

Featured in Daily 8-K Digest

Selected #10 for 2026-09-04. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.